Next Generation

Immuno-Oncology Therapeutics

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.

>> More about immuno-oncology



Phase III-Ready CD95 Ligand Inhibitor

Our lead immuno-oncology candidate APG101 is in clinical development for the treatment of a variety of solid tumors and malignant hematological diseases. It has demonstrated statistically significant efficacy in a controlled phase II proof-of-concept trial in recurrent glioblastoma. Patients with a certain biomarker experienced the greatest benefit from treatment with APG101. Apogenix is developing a companion diagnostic test based on this biomarker, so APG101 can be used as a personalized therapy.



The Apogenix team has created a technology platform for the development of novel fusion proteins that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear therapeutic advantages over other biologics such as antibodies and have the potential for broad application in oncology.



January 14, 2016
Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101

January 7, 2016
Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan